Abstract
PURPOSE: Consumer wearable devices provide new opportunities for measuring patterns of objective daily physical activity throughout cancer treatment. In addition to capturing step counts, these devices can also measure gait cadence and activity fragmentation, two metrics that may reflect functional capacity. The goal of the current study was to examine whether step count, gait cadence, and activity fragmentation predicted overall survival in patients with solid tumors. METHODS: We enrolled patients (N = 213) receiving outpatient chemotherapy for any solid tumor into an observational cohort study. Patients wore a consumer wearable device to measure continuous physical activity patterns for up to 90 days and were followed for a median of 2.53 years, during which 42% of the sample died. Univariable and multivariable Cox proportional hazards regression analyses were used to evaluate associations between wearable device physical function metrics and survival. RESULTS: In univariable analyses, higher step count (hazard ratio (HR), 0.87; P = .007), less activity fragmentation (HR, 1.03; P < .001), and faster peak gait cadence (HR, 0.81; P < .001) were significantly associated with lower mortality risk. Associations with activity fragmentation and gait cadence persisted after adjustment for age and cancer type and stage and after additional adjustment for clinician-rated performance status and patient-reported physical function. CONCLUSION: Activity fragmentation and gait cadence metrics derived from consumer wearable devices were associated with overall survival in patients receiving chemotherapy for any solid tumor. These associations remained statistically significant after adjustment for covariates, including clinician-rated performance status and patient-reported physical function. These findings suggest that wearable devices may capture important prognostic information about physical function independent of what clinicians and patients perceive.